RecruitingGiant Cell Tumor of Bone

Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone

Eligible age

18+ yrs

Accepts

All genders

Locations

12 states

Healthy volunteers

Yes

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of the clinical study is to investigate whether the local delivery of bisphosphonate as a surgical adjuvant can decrease the chance of a giant cell tumor of bone coming back to the same location. The hypothesis is that the local administration of bisphosphonate will decrease the rate of the tumor returning compared to traditional aggressive surgical removal of the tumor.

Sponsor: St. Louis University

You may qualify if…

✓ Primary benign GCT of bone
✓ Lesion located in an extremity
✓ Lesion amenable to reconstruction (intralesional curettage) defined as having at least one intact column of bone after removal
✓ No previous systemic bisphosphonate or denosumab therapy

You may not qualify if…

✕ Recurrent GCT of bone
✕ Non-extremity location
✕ Lesion too extensive for intralesional treatment, either due to bone loss, joint invasion, or large soft tissue component
✕ Children and pregnancy
✕ Previous systemic bisphosphonate or denosumab therapy